CeriBell, Inc. (NASDAQ:CBLL) Stock Has Average Target Price of $31.25 According to Analysts

Shares of CeriBell, Inc. (NASDAQ:CBLL) have received a consensus rating of “Moderate Buy” from the six brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $31.25.

Several analysts recently commented on the stock. BTIG Research reiterated a “buy” rating on shares of CeriBell in a research note on Wednesday. Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 16th. Raymond James Financial reiterated a “strong-buy” rating and issued a $29.00 price target on shares of CeriBell in a research report on Thursday, September 3rd. Barclays raised shares of CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. Finally, Canaccord Genuity Group raised their price target on CeriBell from $26.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday.

Insider Transactions at CeriBell

In other CeriBell news, CTO Raymond Woo sold 4,887 shares of the firm’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $26.96, for a total value of $131,753.52. Following the transaction, the chief technology officer directly owned 203,118 shares of the company’s stock, valued at $5,476,061.28. This trade represents a 2.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Xingjuan Chao sold 20,846 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $25.03, for a total value of $521,775.38. Following the completion of the transaction, the chief executive officer owned 746,345 shares of the company’s stock, valued at approximately $18,681,015.35. This represents a 2.72% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 179,792 shares of company stock worth $4,444,748 in the last quarter. 17.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On CeriBell

Several institutional investors and hedge funds have recently made changes to their positions in CBLL. Sei Investments Co. raised its holdings in CeriBell by 2.3% in the first quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock valued at $923,000 after acquiring an additional 1,125 shares in the last quarter. Strs Ohio acquired a new position in CeriBell during the 1st quarter worth $27,000. Legal & General Group Plc bought a new stake in shares of CeriBell in the 2nd quarter worth about $53,000. State of Wyoming bought a new stake in shares of CeriBell in the 1st quarter worth about $62,000. Finally, Quantinno Capital Management LP raised its stake in shares of CeriBell by 3.0% in the 1st quarter. Quantinno Capital Management LP now owns 140,347 shares of the company’s stock valued at $2,573,000 after purchasing an additional 4,119 shares in the last quarter.

CeriBell Price Performance

CeriBell stock traded up $0.58 during midday trading on Friday, reaching $26.59. The company’s stock had a trading volume of 436,388 shares, compared to its average volume of 562,058. CeriBell has a fifty-two week low of $11.27 and a fifty-two week high of $28.89. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18. The stock’s 50 day simple moving average is $25.25 and its 200 day simple moving average is $20.92. The firm has a market capitalization of $1.02 billion, a PE ratio of -13.71 and a beta of 0.86.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). The company had revenue of $29.34 million for the quarter, compared to analyst estimates of $29.18 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. On average, equities research analysts forecast that CeriBell will post -2.03 earnings per share for the current year.

About CeriBell

CeriBell, Inc is a medical technology company that develops artificial intelligence-enabled neurological diagnostic products. Its technology is designed to help healthcare professionals rapidly identify and monitor seizures, including nonconvulsive seizures that may be difficult to recognize through a standard clinical examination.

The company’s primary product is the Ceribell Rapid Response EEG system, a portable electroencephalography platform that combines a wireless EEG recorder, a simplified disposable headband, and software-based analysis tools.